disialoganglioside GD2

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

March, 2025

disialoganglioside GD2

Jan 23, 2025, 09:49 | Insight

Angela Mastronuzzi: Donor-derived GD2-specific CAR T cells in relapsed or refractory neuroblastoma

Angela Mastronuzzi, President of AIOEP, shared a post on LinkedIn about a recent paper by…

Apr 16, 2024, 01:52 | Insight,Opinion

Angela Mastronuzzi: We investigated whether CAR T-cells directed towards the disialoganglioside GD2 can represent a potentially more effective treatment with reduced long-term side effects

All: 2 Posts: 1 - 100

'

Karen Knudsen has been appointed as the CEO of the Parker Institute for Cancer Immunotherapy

'

Highlights from ELCC 2025

'

FDA Approved Pluvicto (177Lu-PSMA-617) for Metastatic Castration-Resistant Prostate Cancer

'

Meet the New AACR Board of Directores for 2025-2028 Term

'

Do Artificial Sweeteners Cause Cancer? Myths and Facts

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023